-transparent.png){kind=logo}
Decay-accelerating factor (DAF) has been previously described only in cells of bone marrow origin where it serves as a negative modulator of complement activation. Using mAb against human DAF, we demonstrated the presence of DAF in human umbilical vein endothelial cells by immunofluorescence microscopy and flow cytometry. By means of an immunoradiometric assay we detected an average of 3.3 X 10(5) molecules of DAF on each cell. When immunoisolates were analyzed in Western blots, endothelial cell DAF comigrated with DAF purified from normal erythrocytes. DAF was synthesized by the endothelial cells since 35S-labeled DAF could be immunoisolated from HUVEC cultured in medium containing [35S]methionine. This is the first evidence for the presence of DAF in cells of extra-marrow origin. DAF may protect endothelial cells from complement-mediated injury.
A S Asch, and
T Kinoshita, and
E A Jaffe, and
V Nussenzweig
February 1994,
Journal of immunology (Baltimore, Md. : 1950),
A S Asch, and
T Kinoshita, and
E A Jaffe, and
V Nussenzweig
January 1980,
Thrombosis research,
A S Asch, and
T Kinoshita, and
E A Jaffe, and
V Nussenzweig
December 1998,
Fukushima journal of medical science,
A S Asch, and
T Kinoshita, and
E A Jaffe, and
V Nussenzweig
March 1994,
Microvascular research,
A S Asch, and
T Kinoshita, and
E A Jaffe, and
V Nussenzweig
July 1985,
Cell biology international reports,
A S Asch, and
T Kinoshita, and
E A Jaffe, and
V Nussenzweig
July 1994,
The American journal of physiology,
A S Asch, and
T Kinoshita, and
E A Jaffe, and
V Nussenzweig
May 1988,
The Journal of clinical investigation,
A S Asch, and
T Kinoshita, and
E A Jaffe, and
V Nussenzweig
September 2002,
General physiology and biophysics,
A S Asch, and
T Kinoshita, and
E A Jaffe, and
V Nussenzweig
April 1988,
Thrombosis research,
A S Asch, and
T Kinoshita, and
E A Jaffe, and
V Nussenzweig
September 1992,
Surgery,
